159 related articles for article (PubMed ID: 33343369)
1. Evaluation of the Anticancer Activity of a Bile Acid-Dihydroartemisinin Hybrid Ursodeoxycholic-Dihydroartemisinin in Hepatocellular Carcinoma Cells.
Huang TE; Deng YN; Hsu JL; Leu WJ; Marchesi E; Capobianco ML; Marchetti P; Navacchia ML; Guh JH; Perrone D; Hsu LC
Front Pharmacol; 2020; 11():599067. PubMed ID: 33343369
[TBL] [Abstract][Full Text] [Related]
2. Anticancer Activity and Molecular Mechanisms of an Ursodeoxycholic Acid Methyl Ester-Dihydroartemisinin Hybrid via a Triazole Linkage in Hepatocellular Carcinoma Cells.
Hsu YF; Kung FL; Huang TE; Deng YN; Guh JH; Marchetti P; Marchesi E; Perrone D; Navacchia ML; Hsu LC
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903603
[TBL] [Abstract][Full Text] [Related]
3. Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives.
Wu L; Pang Y; Qin G; Xi G; Wu S; Wang X; Chen T
PLoS One; 2017; 12(2):e0171840. PubMed ID: 28182780
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma.
Lim SC; Choi JE; Kang HS; Han SI
Int J Cancer; 2010 Apr; 126(7):1582-95. PubMed ID: 19728331
[TBL] [Abstract][Full Text] [Related]
5. Dihydroartemisinin-Bile Acid Hybridization as an Effective Approach to Enhance Dihydroartemisinin Anticancer Activity.
Marchesi E; Chinaglia N; Capobianco ML; Marchetti P; Huang TE; Weng HC; Guh JH; Hsu LC; Perrone D; Navacchia ML
ChemMedChem; 2019 Apr; 14(7):779-787. PubMed ID: 30724466
[TBL] [Abstract][Full Text] [Related]
6. Dihydroartemisinin-Ursodeoxycholic Bile Acid Hybrids in the Fight against SARS-CoV-2.
Marchesi E; Gentili V; Bortolotti D; Preti L; Marchetti P; Cristofori V; Fantinati A; Rizzo R; Trapella C; Perrone D; Navacchia ML
ACS Omega; 2023 Nov; 8(47):45078-45087. PubMed ID: 38046338
[TBL] [Abstract][Full Text] [Related]
7. The Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy in Hepatocellular Carcinoma Cells.
Wang D; Meng G; Zheng M; Zhang Y; Chen A; Wu J; Wei J
PLoS One; 2016; 11(11):e0166423. PubMed ID: 27835669
[TBL] [Abstract][Full Text] [Related]
8. Effects of low-density lipoprotein docosahexaenoic acid nanoparticles on cancer stem cells isolated from human hepatoma cell lines.
Yang J; Gong Y; Sontag DP; Corbin I; Minuk GY
Mol Biol Rep; 2018 Oct; 45(5):1023-1036. PubMed ID: 30069818
[TBL] [Abstract][Full Text] [Related]
9. Dihydroartemisinin inhibits liver cancer cell migration and invasion by reducing ATP synthase production through CaMKK2/NCLX.
Chang J; Xin C; Wang Y; Wang Y
Oncol Lett; 2023 Dec; 26(6):540. PubMed ID: 38020296
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Biological Evaluation of Artemisinin-Piperazine-Phosphoramide Mustard Hybrids as Potential Anticancer Agents.
Wei MX; Zhang SS; Sun X; Ji Y; Yang PW; Li XQ
ChemMedChem; 2022 Sep; 17(17):e202200239. PubMed ID: 35771689
[TBL] [Abstract][Full Text] [Related]
11. Dihydroartemisinin sensitizes Lewis lung carcinoma cells to carboplatin therapy via p38 mitogen-activated protein kinase activation.
Zhang B; Zhang Z; Wang J; Yang B; Zhao Y; Rao Z; Gao J
Oncol Lett; 2018 May; 15(5):7531-7536. PubMed ID: 29740482
[TBL] [Abstract][Full Text] [Related]
12. Dihydroartemisinin: A Potential Natural Anticancer Drug.
Dai X; Zhang X; Chen W; Chen Y; Zhang Q; Mo S; Lu J
Int J Biol Sci; 2021; 17(2):603-622. PubMed ID: 33613116
[TBL] [Abstract][Full Text] [Related]
13. Influence of oral treatment with ursodeoxycholic and tauroursodeoxycholic acids on estrogen-induced cholestasis in rats: effects on bile formation and liver plasma membranes.
Bouchard G; Yousef IM; Tuchweber B
Liver; 1993 Aug; 13(4):193-202. PubMed ID: 8377596
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a combination of chenodeoxycholic acid and ursodeoxycholic acid for gallstone dissolution: a comparison with ursodeoxycholic acid alone.
Podda M; Zuin M; Battezzati PM; Ghezzi C; de Fazio C; Dioguardi ML
Gastroenterology; 1989 Jan; 96(1):222-9. PubMed ID: 2642440
[TBL] [Abstract][Full Text] [Related]
15. Effect of some sulfonate analogues of ursodeoxycholic acid on biliary lipid secretion in the rat.
Mikami T; Kihira K; Ikawa S; Yoshii M; Mosbach EH; Hoshita T
J Lipid Res; 1996 Jun; 37(6):1181-8. PubMed ID: 8808752
[TBL] [Abstract][Full Text] [Related]
16. Antiproliferative and Apoptotic Effects of Cardamonin against Hepatocellular Carcinoma HepG2 Cells.
Badroon NA; Abdul Majid N; Alshawsh MA
Nutrients; 2020 Jun; 12(6):. PubMed ID: 32545423
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholic acid protects colon cancer HCT116 cells from deoxycholic acid-induced apoptosis by inhibiting apoptosome formation.
Saeki T; Yui S; Hirai T; Fujii T; Okada S; Kanamoto R
Nutr Cancer; 2012; 64(4):617-26. PubMed ID: 22497644
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy.
Goossens JF; Bailly C
Pharmacol Ther; 2019 Nov; 203():107396. PubMed ID: 31356908
[TBL] [Abstract][Full Text] [Related]
19. Acetylshikonin Sensitizes Hepatocellular Carcinoma Cells to Apoptosis through ROS-Mediated Caspase Activation.
Hong M; Li J; Li S; M Almutairi M
Cells; 2019 Nov; 8(11):. PubMed ID: 31752383
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid inhibits overexpression of P-glycoprotein induced by doxorubicin in HepG2 cells.
Komori Y; Arisawa S; Takai M; Yokoyama K; Honda M; Hayashi K; Ishigami M; Katano Y; Goto H; Ueyama J; Ishikawa T; Wakusawa S
Eur J Pharmacol; 2014 Feb; 724():161-7. PubMed ID: 24370495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
